Low incidence rates of mucositis, febrile neutropenia or sepsis in the prospective, randomized phase 3 SIERRA trial for patients with relapsed or refractory acute myeloid leukemia with targeted delivery of anti-CD45 iodine ((131)I) apamistamab [Iomab-B] Meeting Abstract
| Authors: | Natwa, M.; Passalaqua, S.; Chen, M. K.; Wagner, R.; Yap, W.; Griffeth, L.; Wiseman, G.; Mhlanga, J.; Wahl, R.; Avril, N.; Hellman, R.; Lamonica, D.; Matesan, M.; Chasen, B.; Hansen, N.; Leung, E.; Osborne, J.; Peterson, J.; Menda, Y.; Franceschi, D.; Liang, Q.; Reddy, V.; Berger, M.; Pandit-Taskar, N. |
| Abstract Title: | Low incidence rates of mucositis, febrile neutropenia or sepsis in the prospective, randomized phase 3 SIERRA trial for patients with relapsed or refractory acute myeloid leukemia with targeted delivery of anti-CD45 iodine ((131)I) apamistamab [Iomab-B] |
| Meeting Title: | 2021 SNMMI Annual Meeting |
| Journal Title: | Journal of Nuclear Medicine |
| Volume: | 62 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Jun 11-15 |
| Meeting Location: | Virtual |
| ISSN: | 0161-5505 |
| Publisher: | Society of Nuclear Medicine |
| Date Published: | 2021-05-01 |
| Language: | English |
| ACCESSION: | WOS:000713713600784 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1694 -- Source: Wos |
MSK Authors
-
342Pandit-Taskar